Pular para o conteúdo principal
Ranking Invest

BSX - Boston Scientific Corporation

Segmento: HealthcareBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 32.90 Bi
Valor de Mercado
$ 62.29 Bi
Sobrepreço (AV)+89.3%
IVR
0.53A companhia vale 0,53 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.13O valuation alternativo equivale a 13% do valor de mercado da companhia.
MLL
0.13O lucro líquido dos controladores em 16 trimestres equivale a 13% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 24.69 Bi

Dívida Líquida

$ 1.17 Bi

L4T

$ 3.67 Bi

MM4T

17.49%

Indicadores Básicos

ROE

14.86%

Índices de Previsibilidade

Receita Líquida

A0.02

Lucro

B0.20

Margem

B0.20

Índices de Tendência

Receita Líquida

A11.73

Lucro

A10.43

Margem

A9.26

Índices de Endividamento

DIV/PAT

0.05

DIV/L4T

0.32

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.